Combining over 120 years of experience
He recognizes the potential of combining highly specialized experts with the current trends, e.g. such as drug delivery for medicinal Cannabis.
Dr. Lamensdorf founded Pharmaseed in 2003 and has been responsible for its scientific course of expansion, national and international collaborations and staff excellence. He was the founder and CEO of PharmaSense in 2001, a biotechnology company that is specialized in the treatment of CNS disorders. Dr. Lamensdorf serves as the CEO of Thrombotech, bringing its lead compound to Phase IIa. Dr. Lamensdorf holds a Ph.D. in Pharmacology from the Faculty of Medicine of the Technion, Israel Institute of Technology, and a B.S. and M.Sc. in Clinical Pharmacy from the Hebrew University of Jerusalem Medical School. He held postdoctoral positions at the National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH), Bethesda, Maryland and at the Molecular Genetics Department of Israel’s Weizmann Institute of Science.